Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2025 07:00 ET | Source: Larkspur Biosciences, Inc.

Larkspur Biosciences Begins Dosing in Clinical Study of LRK-4189, a First-in-Class Targeted Protein Degrader

Larkspur Biosciences announced the first participant has been dosed in the Phase 1 clinical study of its lead candidate, LRK-4189, in healthy volunteers.